Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...
Biogen (NASDAQ:BIIB) is preparing to release its quarterly earnings on Friday, 2026-02-06. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Biogen ...
Hosted on MSN
Biogen’s (NASDAQ: BIIB) Q4 CY2025: Strong sales
Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results , but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus ...
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table summarizes their recent ratings, shedding light on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results